Abstract：
UNASSIGNED: We sought to assess whether participant enrollment is appropriately representative of the overall urolithiasis population in published urolithiasis clinical trials.
UNASSIGNED: PubMed was queried for urolithiasis US clinical trials published from 2000 to 2022. Trials were evaluated for reporting patient race/ethnicity and sex data. These were then compared to the stone prevalence reported by the National Health and Nutrition Examination Survey from 2015 to 2018. We calculated a representation quotient (RQ) to describe enrollment of patients and then stratified by geographic location, study type, and funding source.
UNASSIGNED: Of the 180 urolithiasis trials performed in the US, we identified 40 trials (22%) reporting race or ethnicity and 104 trials (58%) reporting sex. Male and female participants are well represented (RQ 0.97 and 1.02, respectively). Overall, the RQ of Black, Asian American and Pacific Islander, White, Hispanic, and mixed/other participants is 1.84, 1.06, 1.04, 0.46, and 0.34, respectively. Trials completed in the Western Section and multi-institutional trials have the most proportional enrollment, while trials in the South Central and Southeastern Sections have underrepresentation of mixed/other and Hispanic patients. Enrollment was similar among all trial subtypes. Government- and industry-funded trials had more diverse enrollment than academic-funded trials.
UNASSIGNED: Only 1 in 4 published US urolithiasis trials report race or ethnicity enrollment. Mixed race and Hispanic participants are consistently underrepresented, while Black participants are overrepresented. Government- and industry-sponsored multi-institutional trials have the most proportional representation. Investigators should prioritize inclusive recruitment and improve reporting practices to accurately reflect the diversity of the urolithiasis population.
UNASSIGNED: PubMed was queried for urolithiasis US clinical trials published from 2000 to 2022. Trials were evaluated for reporting patient race/ethnicity and sex data. These were then compared to the stone prevalence reported by the National Health and Nutrition Examination Survey from 2015 to 2018. We calculated a representation quotient (RQ) to describe enrollment of patients and then stratified by geographic location, study type, and funding source.
UNASSIGNED: Of the 180 urolithiasis trials performed in the US, we identified 40 trials (22%) reporting race or ethnicity and 104 trials (58%) reporting sex. Male and female participants are well represented (RQ 0.97 and 1.02, respectively). Overall, the RQ of Black, Asian American and Pacific Islander, White, Hispanic, and mixed/other participants is 1.84, 1.06, 1.04, 0.46, and 0.34, respectively. Trials completed in the Western Section and multi-institutional trials have the most proportional enrollment, while trials in the South Central and Southeastern Sections have underrepresentation of mixed/other and Hispanic patients. Enrollment was similar among all trial subtypes. Government- and industry-funded trials had more diverse enrollment than academic-funded trials.
UNASSIGNED: Only 1 in 4 published US urolithiasis trials report race or ethnicity enrollment. Mixed race and Hispanic participants are consistently underrepresented, while Black participants are overrepresented. Government- and industry-sponsored multi-institutional trials have the most proportional representation. Investigators should prioritize inclusive recruitment and improve reporting practices to accurately reflect the diversity of the urolithiasis population.
摘要：
■我们试图在已发表的尿石症临床试验中评估参与者招募是否适当代表整体尿石症人群。
■PubMed被查询为2000年至2022年发表的美国尿路结石临床试验。评估试验报告患者种族/民族和性别数据。然后将这些与2015年至2018年国家健康和营养检查调查报告的结石患病率进行比较。我们计算了一个代表商（RQ）来描述患者的入组情况，然后按地理位置进行分层，研究类型,和资金来源。
■在美国进行的180项尿石症试验中，我们确定了40项(22%)报告种族或民族的试验和104项(58%)报告性别的试验.男性和女性参与者都有很好的代表性（RQ分别为0.97和1.02）。总的来说,黑色的RQ,亚裔美国人和太平洋岛民，白色,西班牙裔,混合/其他参与者分别为1.84、1.06、1.04、0.46和0.34。在西部部分完成的试验和多机构试验的入学率最高，而在中南部和东南部的试验中，混合/其他和西班牙裔患者的代表性不足。所有试验亚型的登记相似。政府和行业资助的试验比学术资助的试验具有更多样化的入学率。
■只有四分之一的美国尿路结石试验报告种族或种族登记。混合种族和西班牙裔参与者的代表性一直不足，而黑人参与者人数过多。政府和行业赞助的多机构试验具有最大的比例代表性。调查人员应优先考虑包容性招募并改善报告实践，以准确反映尿石症人群的多样性。
■PubMed被查询为2000年至2022年发表的美国尿路结石临床试验。评估试验报告患者种族/民族和性别数据。然后将这些与2015年至2018年国家健康和营养检查调查报告的结石患病率进行比较。我们计算了一个代表商（RQ）来描述患者的入组情况，然后按地理位置进行分层，研究类型,和资金来源。
■在美国进行的180项尿石症试验中，我们确定了40项(22%)报告种族或民族的试验和104项(58%)报告性别的试验.男性和女性参与者都有很好的代表性（RQ分别为0.97和1.02）。总的来说,黑色的RQ,亚裔美国人和太平洋岛民，白色,西班牙裔,混合/其他参与者分别为1.84、1.06、1.04、0.46和0.34。在西部部分完成的试验和多机构试验的入学率最高，而在中南部和东南部的试验中，混合/其他和西班牙裔患者的代表性不足。所有试验亚型的登记相似。政府和行业资助的试验比学术资助的试验具有更多样化的入学率。
■只有四分之一的美国尿路结石试验报告种族或种族登记。混合种族和西班牙裔参与者的代表性一直不足，而黑人参与者人数过多。政府和行业赞助的多机构试验具有最大的比例代表性。调查人员应优先考虑包容性招募并改善报告实践，以准确反映尿石症人群的多样性。
